Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
123.07
-0.22 (-0.18%)
Nov 4, 2024, 4:00 PM EST - Market closed
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for SRPT stock have an average target of 183.65, with a low estimate of 109 and a high estimate of 230. The average target predicts an increase of 49.22% from the current stock price of 123.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SRPT stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 9 | 10 | 11 | 11 | 12 | 12 |
| Hold | 4 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $182 | Buy | Reiterates | $182 | +47.88% | Oct 21, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $165 | Strong Buy | Initiates | $165 | +34.07% | Oct 21, 2024 |
| Needham | Needham | Strong Buy Reiterates $205 | Strong Buy | Reiterates | $205 | +66.57% | Oct 14, 2024 |
| Raymond James | Raymond James | Buy Initiates $150 | Buy | Initiates | $150 | +21.88% | Oct 10, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $181 → $182 | Buy | Maintains | $181 → $182 | +47.88% | Oct 4, 2024 |
Financial Forecast
Revenue This Year
1.78B
from 1.24B
Increased by 43.24%
Revenue Next Year
3.19B
from 1.78B
Increased by 79.28%
EPS This Year
1.68
from -5.80
EPS Next Year
11.21
from 1.68
Increased by 565.96%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.0B | 3.8B | 4.6B | ||
| Avg | 1.8B | 3.2B | 3.8B | ||
| Low | 1.5B | 2.9B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 63.0% | 110.8% | 42.5% | ||
| Avg | 43.2% | 79.3% | 18.9% | ||
| Low | 22.5% | 63.1% | -47.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.42 | 16.78 | 21.13 | ||
| Avg | 1.68 | 11.21 | 14.23 | ||
| Low | 0.26 | 7.23 | 8.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 896.4% | 88.4% | ||
| Avg | - | 566.0% | 26.9% | ||
| Low | - | 329.5% | -25.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.